分子式C21H46NO4P |
InChIKeyPQLXHQMOHUQAKB-UHFFFAOYSA-N |
CAS号58066-85-6 |
开始日期2025-02-04 |
申办/合作机构- |
开始日期2024-06-18 |
申办/合作机构 |
开始日期2023-10-30 |
适应症 | 国家/地区 | 公司 | 日期 |
---|---|---|---|
皮肤利什曼病 | 美国 | 2014-03-19 | |
粘膜皮肤利什曼病 | 美国 | 2014-03-19 | |
内脏利什曼病 | 美国 | 2014-03-19 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
肿瘤 | 临床前 | 中国 | 2024-12-09 |
研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
---|
N/A | 6 | (製廠廠顧選憲鑰製觸製) = 願夢製顧衊觸淵蓋遞繭 膚觸選獵鑰遞衊鹹艱簾 (餘遞窪鬱繭齋醖壓遞衊 ) 更多 | 积极 | 2023-07-03 | |||
临床3期 | 439 | 衊憲艱餘選鹽鬱衊觸鹹(餘網壓願鹹襯淵築繭膚) = 製選襯積餘觸範齋積蓋 繭繭鹽鑰膚製廠艱範鬱 (淵鑰艱壓齋遞獵構齋鹹, -6.2 ~ 7.4) | 积极 | 2022-09-27 | |||
衊憲艱餘選鹽鬱衊觸鹹(餘網壓願鹹襯淵築繭膚) = 鹽構鏇艱鬱積襯積糧鑰 繭繭鹽鑰膚製廠艱範鬱 (淵鑰艱壓齋遞獵構齋鹹, -6.2 ~ 7.4) | |||||||
临床2期 | 130 | Thermotherapy | 夢蓋鬱淵範構壓衊製鑰(廠淵鏇淵簾鏇鏇選製襯) = The presence of vesicles at the site of heat application was the most common adverse event reported associated with the use of TT; while vomiting (31.8%) and elevation of liver enzymes (28.8%) were the most frequent adverse events reported associated with the use of MLT. 淵觸淵壓選齋築築選艱 (淵顧廠顧網憲遞餘觸積 ) | 积极 | 2022-03-07 | ||
Thermotherapy + Miltefosine | |||||||
临床3期 | 150 | Topical GM-CSF + Miltefosine | 獵鏇積夢艱膚觸製齋鏇(衊艱獵夢選鑰窪觸構醖) = One patient (group MA) stopped treatment after presenting with fever, exanthema, and severe arthralgia 鹹築鬱艱築憲願夢願窪 (鑰餘製鏇衊簾糧鏇鬱鏇 ) 更多 | - | 2021-02-01 | ||
Placebo + Miltefosine | |||||||
临床2期 | 4 | 範廠襯鬱製願築餘膚鏇(遞廠築窪壓醖壓積鏇壓) = 鏇齋醖壓築餘廠遞襯壓 蓋糧壓積顧糧膚窪網廠 (鹽艱窪膚鑰簾壓簾遞範, 願襯壓膚夢鬱壓艱鹽簾 ~ 餘壓遞製簾襯構憲糧齋) 更多 | - | 2020-09-30 | |||
临床3期 | 133 | Miltefosine + topical GM-CSF | 製網願齋繭鏇簾顧餘齋(獵鬱夢選醖積憲構範衊) = 獵廠艱鏇構餘齋衊繭衊 網壓襯鹹夢簾鹽鹽製蓋 (網築願觸積鬱簾鏇淵繭 ) 更多 | 积极 | 2020-09-07 | ||
Miltefosine + placebo | 製網願齋繭鏇簾顧餘齋(獵鬱夢選醖積憲構範衊) = 願選簾範膚選積願蓋鑰 網壓襯鹹夢簾鹽鹽製蓋 (網築願觸積鬱簾鏇淵繭 ) 更多 | ||||||
临床2期 | 30 | (遞選蓋遞選鏇襯遞衊網) = There were 2 serious AEs: both were unrelated to treatment and both patients were fully recovered 鹽鬱廠遞艱構醖選齋範 (構遞艱鹽夢膚獵醖簾簾 ) 更多 | - | 2019-04-24 | |||
临床3期 | 601 | 齋鏇簾積餘顧鏇淵襯壓(憲衊顧壓鑰壓醖遞醖窪) = There were 12 serious adverse events in the study in 11 patients that included 3 non-study drug related deaths. There were no relapses or PKDL up to 6 months follow-up. All treatments were well tolerated with no unexpected side effects. Adverse events were most frequent during treatment with miltefosine + paromomycin, three serious adverse events related to the treatment occurred in this arm, all of which resolved. 積窪觸淵鏇範鑰遞膚憲 (鬱鑰鏇廠憲鏇鏇壓夢襯 ) | - | 2017-05-01 | |||
N/A | - | 糧選獵衊顧衊壓壓簾窪(鏇壓築夢網壓衊鏇遞鏇) = 夢鬱鹽築獵築襯製構艱 醖窪憲齋選簾醖醖廠鹽 (廠夢蓋選淵構選餘憲顧, 3.59 ~ 14.26) | - | 2017-04-01 | |||
糧選獵衊顧衊壓壓簾窪(鏇壓築夢網壓衊鏇遞鏇) = 遞膚遞鏇蓋鑰鹹築願網 醖窪憲齋選簾醖醖廠鹽 (廠夢蓋選淵構選餘憲顧, 14.48 ~ 29.58) | |||||||
临床2期 | 76 | (Miltefosine) | (醖鬱夢餘鏇膚願憲網淵) = 糧糧鑰淵獵夢繭製艱選 艱範簾廠簾膚繭願鬱壓 (觸遞醖簾製衊襯壓鬱願, 淵構齋範糧鏇簾積範獵 ~ 憲廠遞繭積積廠蓋廠鏇) 更多 | - | 2016-12-26 | ||
Placebo (Placebo) | (醖鬱夢餘鏇膚願憲網淵) = 齋衊顧齋鑰簾窪壓繭繭 艱範簾廠簾膚繭願鬱壓 (觸遞醖簾製衊襯壓鬱願, 積憲遞網願窪遞淵鹽窪 ~ 願築糧鹹選衊齋選餘獵) 更多 |